<DOC>
	<DOCNO>NCT01540799</DOCNO>
	<brief_summary>The purpose clinical study evaluate use implant sphenopalatine ganglion ( SPG ) neurostimulator treatment migraine headache pain , migraine headache symptom migraine frequency high disability migraineurs .</brief_summary>
	<brief_title>Pathway M-1 : Sphenopalatine Ganglion Stimulation AcuteTreatment High Disability Migraine Headache</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Ganglion Cysts</mesh_term>
	<mesh_term>Synovial Cyst</mesh_term>
	<criteria>Age â‰¥ 18 year old . Subject diagnose least 3 month prior study enrollment migraine headache without aura accord 2004 ICHDII criteria 1.1 1.2.1.1 . Subject report least 75 % migraine attack predominantly fix ( non sideshifting ) unilateral temporal ocular pain . Subject report moderate/severe migraine pain typically precede mild pain phase . Subject report minimum 8 day per month maximum 14 day per month migraine attack least moderate severity base subject/Investigator 's knowledge least 3 month prior inclusion confirm least 1 month PreImplant Baseline Period use Pathway M1 Daily Headache Diary . Subject report least 24 hour painfree period typical migraine attack . Subject MIDAS grade III IV , HIT6 score &gt; 56 . Subject medically intractable opinion Investigator . Subject stable type dosage preventive headache medication least 1 month prior study enrollment agrees maintain stable type dosage preventive headache medication completion Experimental Period . Subject able distinguish migraine attack headache ( i.e. , TTH ) . Subject agree participate supplemental alternative therapy Open Label phase study . This include : acupuncture , spinal manipulation , TENS , magnetic field treatment . Subject ability read , comprehend , reliably record information require Protocol . Subject able provide write informed consent prior participation study . Subject 's overall health , age and/or comorbidities place subject high risk complication surgery and/or general anesthesia . Subject diagnose chronic migraine last year accord 2006 ICHDIIR Appendix 1.5.1 . Subject currently Medication Overuse Headache ( MOH ) history MOH last year accord ICHD2R 2006 criterion . Subject use triptans , pain medication analgesic kind indication 14 day per month last three month . Subject report continuous daily headache one month long time consent . Subject report initial onset migraine within last year . Subject undergone facial surgery metallic implant area pterygopalatine fossa zygomaticomaxillary buttress ipsilateral plan implant site , opinion Investigator , may lead inability properly implant use Neurostimulator . Subject active oral dental abscess . Subject treat therapeutic radiation facial region . Subject diagnose major infectious process osteomyelitis , primary secondary malignancy involve face active require treatment past 6 month require periodic MRI followup . Subject 's pterygomaxillary fissure le 1.2 mm width level vidian canal , determine CT scan . Subject clinically significant drug ( include opioid ) alcohol abuse define DSMIVTR , likely unable refrain substance abuse throughout study , significant pain problem , substance abuse active depressive episode might confound study assessment opinion Investigator . Subject currently participate participate last month another clinical study subject , , expose investigational drug device . Subject felt risk noncompliance ( e.g. , complete diary , maintain stable headache medicine regimen return require followup visit ) Investigator 's opinion . Subject woman childbearing age pregnant , nursing , use contraception . A sterilized infertile woman exempt requirement use contraception . Subject previous lesional radiofrequency ablation ipsilateral sphenopalatine ganglion ( SPG ) . Subject block nonlesional pulse RF ipsilateral SPG last 3 month . Subject undergone botulinium toxin injection head and/or neck last 3 month . Subject require pacemaker/defibrillator implantable device sense amplifier program 'On . ' Subject history bleeding disorder coagulopathy unable discontinue anticoagulation , antiplatelet , GP IIb IIIa inhibitor medication preparation implantation procedure . Subject chronic neurological illness face ( e.g. , facial nerve paralysis , trigeminal neuralgia ) . Subject suitable study reason judgment Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Migraine</keyword>
	<keyword>High disability migraine</keyword>
	<keyword>Sphenopalatine ganglion</keyword>
	<keyword>Neuromodulation</keyword>
	<keyword>Neurostimulation</keyword>
	<keyword>Autonomic nervous system</keyword>
</DOC>